Brown, AH;
Shah, S;
Groves, AM;
Wan, S;
Malhotra, A;
(2021)
The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination.
Clinical Nuclear Medicine
, 46
(12)
pp. 1006-1010.
10.1097/RLU.0000000000003683.
Preview |
Text
Groves_Manuscript v2 - PET covid lymph nodes breast cancer staging.pdf - Accepted Version Download (185kB) | Preview |
Abstract
We report a case series of biopsy-proven reactive axillary lymph nodes, which were avid on FDG PET/CT in breast cancer patients post COVID-19 vaccination. With 4 cases presenting in a consecutive 10-day period, it became apparent that metabolically active axillary lymphadenopathy is an adverse effect of COVID-19 vaccines, currently being deployed worldwide. This may lead to patients undergoing unnecessary biopsy. We have started taking a COVID-19 vaccine status history before PET/CT. If enlarged/metabolically active axillary nodes are identified in the ipsilateral vaccinated arm, then axillary ultrasound at 4 weeks is suggested.
Archive Staff Only
 |
View Item |
